Rowasa

Proctitis, Proctocolitis, Colitis, Ulcerative + 2 more

Treatment

1 FDA approval

0 Active Studies for Rowasa

What is Rowasa

Mesalazine

The Generic name of this drug

Treatment Summary

Mesalazine is an anti-inflammatory medication related to aspirin and other non-steroidal anti-inflammatory drugs. It is used to treat and maintain remission for ulcerative colitis. Over the years, researchers have developed medications that contain mesalazine in more stable forms, such as Asacol and Pentasa. Recent studies have also looked into the potential of mesalazine to reduce inflammation and possibly lower the risk of colorectal cancer in people with ulcerative colitis.

Rowasa

is the brand name

Rowasa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rowasa

Mesalazine

1988

107

Approved as Treatment by the FDA

Mesalazine, otherwise called Rowasa, is approved by the FDA for 1 uses which include Crohn Disease .

Crohn Disease

Effectiveness

How Rowasa Affects Patients

Mesalazine is one of two components in sulphasalazine, a medication used to treat ulcerative colitis. It is thought to reduce inflammation by blocking the production of certain substances that cause inflammation, like prostaglandins and leukotrienes, and also by neutralizing free radicals. Studies have shown that mesalazine given orally or directly into the abdomen can help reduce inflammation in mice and guinea pigs with colitis.

How Rowasa works in the body

Mesalazine works to reduce inflammation in the colon. It does this by blocking certain pathways that increase inflammation, such as the production of prostaglandins and leukotrienes. It also works by inhibiting Nuclear Factor kappa B, which helps reduce pro-inflammatory cytokines. Mesalazine also has the potential to activate PPAR gamma receptors and inhibit iNOS, which helps lower inflammation in the intestine. Finally, mesalazine also decreases leukocyte chemotaxis, decreases cytokines and leukotrienes, and scavenges for free radicals, helping reduce inflammation overall.

When to interrupt dosage

The measure of Rowasa is contingent upon the diagnosed condition. The quantity of dosage shifts, as per the method of delivery stated in the table below.

Condition

Dosage

Administration

Proctitis

400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg

, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Tablet, extended release, Tablet, extended release - Oral, Suppository, Suppository - Rectal, Suspension, Suspension - Rectal, Enema, Enema - Rectal, Rectal, Enema; Liquid - Rectal, Enema; Liquid, Kit, Capsule, extended release - Oral, Capsule, extended release, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal

Ulcerative Colitis

400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg

, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Tablet, extended release, Tablet, extended release - Oral, Suppository, Suppository - Rectal, Suspension, Suspension - Rectal, Enema, Enema - Rectal, Rectal, Enema; Liquid - Rectal, Enema; Liquid, Kit, Capsule, extended release - Oral, Capsule, extended release, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal

Proctocolitis

400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg

, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Tablet, extended release, Tablet, extended release - Oral, Suppository, Suppository - Rectal, Suspension, Suspension - Rectal, Enema, Enema - Rectal, Rectal, Enema; Liquid - Rectal, Enema; Liquid, Kit, Capsule, extended release - Oral, Capsule, extended release, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal

Crohn Disease

400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg

, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Tablet, extended release, Tablet, extended release - Oral, Suppository, Suppository - Rectal, Suspension, Suspension - Rectal, Enema, Enema - Rectal, Rectal, Enema; Liquid - Rectal, Enema; Liquid, Kit, Capsule, extended release - Oral, Capsule, extended release, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal

Colitis, Ulcerative

400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg

, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Tablet, extended release, Tablet, extended release - Oral, Suppository, Suppository - Rectal, Suspension, Suspension - Rectal, Enema, Enema - Rectal, Rectal, Enema; Liquid - Rectal, Enema; Liquid, Kit, Capsule, extended release - Oral, Capsule, extended release, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal

Warnings

Rowasa has eight contraindications. It should not be administered when suffering from any of the afflictions in the following table.

Rowasa Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Mesalazine may interact with Pulse Frequency

There are 20 known major drug interactions with Rowasa.

Common Rowasa Drug Interactions

Drug Name

Risk Level

Description

Macimorelin

Major

The therapeutic efficacy of Macimorelin can be decreased when used in combination with Mesalazine.

Methotrexate

Major

The serum concentration of Methotrexate can be increased when it is combined with Mesalazine.

Mifamurtide

Major

The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mesalazine.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neomycin.

Omacetaxine mepesuccinate

Major

The risk or severity of bleeding can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.

Rowasa Toxicity & Overdose Risk

In rat studies, no increase in cancer risk was found with up to 1.7 times the recommended human dose of mesalazine. The drug was also not found to be mutagenic. No fertility or reproductive problems were reported in male or female rats at this dose. Symptoms of an overdose include nausea, vomiting, breathing difficulties, ringing in the ears, and confusion. In more severe cases, electrolyte and pH levels can become unbalanced and other organs can be affected. There is no specific antidote; however, conventional treatments for salicylate toxicity can help reduce the effects of an overdose. People with kidney disease or a history

image of a doctor in a lab doing drug, clinical research

Rowasa Novel Uses: Which Conditions Have a Clinical Trial Featuring Rowasa?

At present, 96 active studies are assessing the utility of Rowasa in the management of Ulcerative Colitis.

Condition

Clinical Trials

Trial Phases

Proctocolitis

0 Actively Recruiting

Proctitis

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Colitis, Ulcerative

0 Actively Recruiting

Ulcerative Colitis

0 Actively Recruiting

Rowasa Reviews: What are patients saying about Rowasa?

5

Patient Review

7/21/2010

Rowasa for Ulcerated Colon

Ulcerative colitis is a tough condition to deal with, but this medication has been incredibly effective for me and my family. We've all been using it for years with great results.

5

Patient Review

12/18/2012

Rowasa for Inflammation of the Sigmoid Colon and the Rectum

This has been my go-to twice now for flares of ulcerative colitis. Within a week, the blood and mucous stopped--and I experienced zero side effects.

5

Patient Review

10/20/2016

Rowasa for Ulceration of the Rectum

Though it's not the most pleasant experience, this medication offers quick and effective relief whenever I'm in pain.

3.3

Patient Review

1/21/2009

Rowasa for Ulcerated Colon

Rowasa is effective at stopping flares, but my doctor wants me to use it EVERY night. I'd rather not enema myself every night, so we'll see how the Asacol goes.

3.3

Patient Review

6/21/2008

Rowasa for Inflammation of the Sigmoid Colon and the Rectum

Rowasa can sometimes be difficult to hold in for the entire night.

2

Patient Review

5/24/2010

Rowasa for Ulcerated Colon

I've used this medication in the past, but it seems to have made my symptoms worse rather than better. I stopped taking it a few days ago and have been feeling much better since then.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rowasa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is Rowasa taken?

"Insert the suppository gently into the rectum with your finger, pointed end first. You may want to use a small amount of lubricating gel on the tip of the suppository. Stay lying down for a few minutes. Try not to have a bowel movement for 1 to 3 hours, so the medicine can work."

Answered by AI

What is Rowasa used for?

"Mesalamine is a drug that is used to treat ulcerative colitis, which is an inflammatory bowel condition. The drug is available in the form of an enema, which is designed to lower swelling and inflammation in the colon. However, the drug can sometimes cause allergic reactions."

Answered by AI

How does a Rowasa enema work?

"Mesalamine is an aminosalicylate anti-inflammatory drug which is thought to work by hindering the creation of certain natural chemicals that can lead to pain and swelling."

Answered by AI

How quickly does Rowasa work?

"It usually takes 3 to 6 weeks to see the full effect of ROWASA® (mesalamine) Rectal Suspension Enema, although some people may see a difference within 3 to 21 days."

Answered by AI